Advaxis: Immunotherapy nano-cap Advaxis withdraws $9 million Nasdaq uplisting

Advaxis, which is developing neoantigen-directed immunotherapies for cancer, withdrew its plans for an initial public offering on Monday, reported Renaissance Capital. It had filed in May and had mo...